Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable melanoma
2014-001146-13Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2014
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of talimogene laherparepvec in melanoma (2 arms), sponsored by Amgen. Primary endpoint: Recurrence-free survival. Started Oct 2014; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-001146-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001146-13.